MAGEA1 and neoplasm: ICT-107 is a DC vaccine derived from autologous or monocyte-derived DCs, which target six antigens on tumor cells, including glycoprotein 100, IL-13Rα2, tyrosinase-related protein-2, antigen isolated from immunoselected melano-ma-2, the HLA-A2-restricted human EGFR-2 (HER2/neu), and the HLA-A1-restricted melanoma-associated antigen-1 [120].